Receptor BioLogix Overview

  • Founded
  • 2003

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

Receptor BioLogix General Information


Developer of receptor based biological therapeutics for cancer and other diseases. The company offers Hermodulins, pan-HER ligand traps designed to inhibit the compensatory feedback mechanisms that limit the efficacy and durability of various cancer drugs, as well as demonstrates anti-cancer potential in preclinical studies. It also develops Intron Fusion Protein platform for the discovery of novel alternative forms-splice variants-of human proteins with therapeutic potential.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 3350 West Bayshore Road
  • Suite 150
  • Palo Alto, CA 94303
  • United States
+1 (650) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Receptor BioLogix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 29-Jan-2009 000.00 Completed Product Development
1. Early Stage VC (Series A) 28-Oct-2008 000.00 000.00 Completed Product Development
To view Receptor BioLogix’s complete valuation and funding history, request access »

Receptor BioLogix Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Domain Associates Venture Capital Minority 000 0000 000000 0
EW Healthcare Partners Growth/Expansion Minority 000 0000 000000 0
MedImmune Ventures Corporate Venture Capital Minority 000 0000 000000 0
New Science Ventures Venture Capital Minority 000 0000 000000 0
Northwest Technology Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »